Search Results for “” – OSLM

OSLM

Outcome Studies
in Laboratory Medicine

guest

👤

Learn more about this platform

Project:Cancer

Categories:Clinical outcomes RCT

6 Publications found

Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.

b

Annals of oncology : official journal of the European Society for Medical Oncology

November 1, 2020

p Cancer

c Change patient management Clinical outcomes RCT
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.

b

The Lancet. Respiratory medicine

November 1, 2020

p Cancer

c Change patient management Clinical outcomes RCT
Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.

b

Cancer science

September 1, 2019

p Cancer

c Change patient management Clinical outcomes RCT
Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.

b

Cancer science

June 1, 2018

p Cancer

c Change patient management Clinical outcomes RCT
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

b

The New England journal of medicine

November 9, 2017

p Cancer

c Change patient management Clinical outcomes Highlighted RCT
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

b

The New England journal of medicine

February 16, 2017

p Cancer

c Change patient management Clinical outcomes RCT